This segment focuses on the development and commercialization of PEDMARK® (sodium thiosulfate) to reduce the risk of platinum-induced ototoxicity in pediatric cancer patients undergoing chemotherapy. Research and development activities are centered on optimizing the formulation and delivery of PEDMARK® to maximize its protective effects on hearing. The segment addresses a critical unmet need in pediatric oncology, as cisplatin-based chemotherapy can lead to permanent hearing loss in children, impacting their quality of life and development. Fennec's market positioning is centered on establishing PEDMARK® as the standard of care for ototoxicity prevention in this patient population. Future opportunities include expanding the use of PEDMARK® to other chemotherapy regimens and exploring its potential in preventing ototoxicity in adult cancer patients. Regulatory and clinical aspects involve ongoing monitoring of PEDMARK®'s safety and efficacy, as well as compliance with FDA guidelines.